Picture loading failed.

Anti-IL6R therapeutic antibody (Pre-made Satralizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-509-1mg 1mg 3090
GMP-Bios-ab-509-10mg 10mg 21890
GMP-Bios-ab-509-100mg 100mg 148000
GMP-Bios-ab-509-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL6R therapeutic antibody (Pre-made Satralizumab biosimilar,Whole mAb)
INN Name Satralizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2017
CompaniesChugai Pharmaceutical;Roche
Conditions ApprovedNeuromyelitis optica
Conditions Activena
Conditions DiscontinuedRheumatoid arthritis
Development Techna